| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8528956 | European Journal of Pharmacology | 2018 | 26 Pages | 
Abstract
												The aim of this study was to investigate whether scopoletin could inhibit the activities of the carbohydrate digestive enzymes, α-glucosidase and α-amylase, and reduce postprandial hyperglycemia in streptozotocin (STZ)-induced diabetes in mice. Scopoletin showed a distinct inhibitory effect on α-glucosidase and α-amylase. The half maximal inhibitory concentration (IC50) of scopoletin was 85.12 and 37.36â¯Î¼M for α-glucosidase and α-amylase, respectively, which were lower values than those for acarbose. The increase in postprandial blood glucose levels was significantly suppressed in the scopoletin group compared to the control group of STZ-induced diabetes in mice. Moreover, the area under the curve significantly decreased with the administration of scopoletin in STZ-induced diabetes in mice. These results showed that scopoletin might help to lower postprandial hyperglycemia through inhibition of carbohydrate digestive enzymes.
											Related Topics
												
													Life Sciences
													Neuroscience
													Cellular and Molecular Neuroscience
												
											Authors
												June Hyuk Jang, Jae Eun Park, Ji Sook Han, 
											